Skip to content

Validation of miRNA signatures for the early detection of lung cancer

Validation of miRNA signatures for the early detection of lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00013647
Enrollment
303
Registered
2018-02-05
Start date
2018-02-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Blood draw from patients with suspected lung tumor Group 2: Blood draw from patients undergoing bronchoscopic evaluation of suspected non-malignant pulmonary diseases.

Sponsors

Hummingbird Diagnostics GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female with presumable pathological findings through X-ray/CT 2. Signed informed consent 3. Patient is at least 18 years old

Exclusion criteria

Exclusion criteria: 1. History of other primary malignancies 2. Medication that influences the immune system (e.g. immunosuppressive drugs) 3. Patient is younger than 18 years

Design outcomes

Primary

MeasureTime frame
Validation of a previously identified signature of blood-based miRNA biomarkers for the identification of lung tumors. After measuring miRNA expression levels, it will be tested whether the signature can be used to discriminate between the two cohorts and if the results are comparable to previous tests.

Secondary

MeasureTime frame
Testing the potential of a previously identified signature of blood-based miRNA biomarkers for lung cancer screening.

Countries

Germany

Contacts

Public ContactStephan Walterspacher

Klinikum Konstanz Lungenzentrum / II. Medizinische Klinik

stephan.walterspacher@glkn.de07531-801-1451

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026